글로벌 종양 전사체 시장 – 2029년까지의 산업 동향 및 예측

종양 전사체 시장 분석 및 규모

세계보건기구(WHO)에 따르면 암은 전 세계적으로 두 번째로 큰 사망 원인으로, 사망자 6명 중 거의 1명을 차지합니다. 2020년에는 암 관련 사망자가 전 세계적으로 1,000만 명에 가까워질 것으로 예상됩니다. 소아암 유병률 증가도 시장 확대를 촉진할 것으로 예상되는 중요한 요인입니다. WHO 보고서에 따르면, 매년 0~19세의 어린이 40만 명이 암 진단을 받습니다. 또한, 의료 전문가들이 암 치료에 유전학을 활용하면서 시장 확대에 도움이 될 것으로 예상됩니다.

Data Bridge Market Research는 2021년에 71억 5천만 달러였던 종양 전사체 시장이 2029년까지 158억 4천만 달러로 급증할 것으로 분석했으며, 2022년부터 2029년까지의 예측 기간 동안 10.45%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

종양 전사체 시장 범위 및 세분화      

Market Definition

Transcriptomics technologies are the techniques used to study an organism's transcriptome, the sum of its RNA transcripts. There are many uses for transcriptomics, most notably in molecular genetics, which involves studying and collecting transcriptomes. The worldwide transcriptomics market may see numerous new product introductions.

Tumor Transcriptomics Market Dynamics

Drivers

• Rising metastasis analysis

Several factors, including the expanding application of spatial genomic interpretation as a melanoma indicative medium, the tumor's advancing rate, and increasing metastasis analysis and investments, the market for tumour transcriptomics is predicted to grow strongly over the forecast period. The fourth genome sequencing span's appearance and emerging professionals' ability to advance the industry are two other factors driving the business expansion.

• Increasing consumers demand

The market for transcriptomics technologies is being supported by ongoing technological advancement, the launch of trustworthy and effective procedures, and rising consumer demand for more dependable and compact solutions.

Opportunities

The demand for tumour transcriptomics is anticipated to increase due to the increasing knowledge among doctors and patients about the advantages of using sequencing techniques and treatments derived from transcriptomics methods to combat cancer.

Restraints/Challenges

On the other hand, the high capital investment, poor regulatory and reimbursement scenario and slow implementation of technology will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.

This tumor transcriptomics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tumor transcriptomics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Tumor Transcriptomics Market

The COVID-19 pandemic has had an influence on the market and on the healthcare systems. A critical source of possible clinical indicators for clinical decision-making has recently emerged from transcriptomic profiling of liquid biopsies, particularly microRNAs (miRNAs). Furthermore, nations have had and continue to experience a substantial strain on their economies and healthcare systems, which has resulted in the closure of research and academic institutions. The sales of reagents and supplies used in transcriptomics analysis have decreased. According to Nanostring Technologies Inc.'s 2020 annual report, the company's Consumables section had a sharp fall of 18% from 2019.

Recent Development

• In March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.
• In April 2020, An international collaborative alliance to improve customised medication in cancer using IndivuType, the business's multi-omics database, was established by the oncology company Indivumed GmbH.

Global Tumor Transcriptomics Market Scope

The tumor transcriptomics market is segmented on the basis of tumor type, technology, product and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Tumor Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Others

Technology

• Microarray
• Real-Time Quantitative
• Polymerase Chain Reaction (Q-PCR)
• Sequencing Technologies

Product

• Consumables
• Instrument
• Others

Application

• Diagnostics
• Disease Profiling
• Drug Discovery
• Others

Tumor Transcriptomics Market Regional Analysis/Insights

The tumor transcriptomics market is analysed and market size insights and trends are provided by country, tumor type, technology, product and application as referenced above.

The countries covered in the tumor transcriptomics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the tumor transcriptomics market due to the great pervasiveness of breast malignancy sufferers.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to attraction of various organized business professionals to augment their occupancy in this singular domain.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 종양 전사체 시장 점유율 분석

종양 전사체 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 종양 전사체 시장과 관련된 회사의 초점에만 관련이 있습니다.

종양 전사체 시장에서 활동하는 주요 기업은 다음과 같습니다.

• Agilent Technologies, Inc. (미국)
• F. Hoffmann-La Roche AG(스위스)
• Bio-Rad Laboratories, Inc. (미국)
• 제너럴 일렉트릭(미국)
• Fluidigm Corporation(미국)
• 일루미나 주식회사(미국)
• 10x Genomics(미국)
• 팩바이오(미국)
• 머크 샤프 앤 도메 코퍼레이션(미국)
• 프로메가 코퍼레이션(미국)
• QIAGEN(독일)
• Thermo Fisher Scientific Inc. (미국) 

SKU-52904